NEW YORK / Mar 28, 2023 / Business Wire / DocGo (Nasdaq: DCGO), a leading provider of last-mile mobile health services, announced today that Anthony Capone, CEO, will be participating on a panel at HIMSS23 in Chicago, speaking on the topic of a “Virtual First Approach to Augment Consumer Care Delivery at Home.” This important panel, led by Kent Dicks, Founder and CEO of Life365, will explore the latest opportunities and challenges to effectively implement a virtual first approach to delivering home health care and the outlook for its demand and adoption. In addition to Capone, John Bennett, Healthcare Industry Specialist at Microsoft Corporation, will round out the panel participants.
The event will take place from 3:00 PM – 4:00 PM on Tuesday, April 18th, in the South Building, Level 5, Room S501.
“I’m looking forward to discussing virtual care technology solutions that can be used to maximize patient engagement, increase access to care, and enhance clinical decision making,” said Capone. “Virtual care is the next logical step for healthcare organizations and clinicians to simplify workflows and improve patient outcomes.”
To register for HIMSS, please visit here.
About DocGo
DocGo is a leading provider of last-mile mobile care services. DocGo is disrupting the traditional four-wall healthcare system by providing high quality, highly affordable care to patients where and when they need it. DocGo's innovative technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with Ambulnz by DocGo's integrated medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.
All third-party trademarks used in this release are the property of their respective owners.
Last Trade: | US$3.50 |
Daily Change: | -0.01 -0.28 |
Daily Volume: | 566,122 |
Market Cap: | US$364.600M |
April 10, 2024 February 28, 2024 December 19, 2023 November 06, 2023 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB